News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 9084S

9084S 5 mg

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Western blot analysis of extracts from K-562 cells, untreated (-) or treated with imatinib (10 μM, 1 hr; +), using PathScan® Bcr/Abl Activity Assay: Phospho-c-Abl, Phospho-Stat5 and Phospho-CrkL Multiplex Western Detection Cocktail #5300 to detect inhibition of phospho-Bcr-Abl, phospho-Stat5, and phospho-CrkL.

Learn more about how we get our images

Chemical structure of imatinib.

Learn more about how we get our images
Image

Product Usage Information

Imatinib is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 847.9 μl DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 1-10 μM for 1-2 hours. Soluble in DMSO at 100 mg/ml; poorly soluble in ethanol. Soluble in water at 200 mg/ml.


Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

589.71 g/mol


Purity:

>99%


Molecular Formula:

C29H31N7O + CH4SO3


Imatinib is a tyrosine kinase (TK) inhibitor that is a relatively specific ATP-binding site antagonist of Bcr-Abl, PDGF receptor, and c-Kit TKs (1-3). Results are encouraging in chronic myeloid leukemia (CML) clinical trials and imatinib has become a paradigm for targeted cancer therapeutics (4-6). Signal transduction through phospho-tyrosine pathways has been studied extensively, and tyrosine phosphorylation has been linked to multiple cell growth and differentiation pathways (7-9). Because the observed leukemic state of CML is dependent on the intact Bcr-Abl tyrosine kinase activity, extensive work has been done to identify substrates of Bcr-Abl and thus possible mechanisms leading to a myeloid expansion. Many groups have characterized prominent tyrosine-phosphorylated protein substrates in both CML blasts and Bcr-Abl-expressing cell lines, including SHIP, c-Cbl, Dok, Shc, and CrkL (10-15). In addition, key signal transduction pathways involving PI3 kinase, Ras, Myc, and Stat5 are also activated in a Bcr-Abl kinase-dependent manner (16).


1.  Buchdunger, E. et al. (1996) Cancer Res 56, 100-4.

2.  Heinrich, M.C. et al. (2000) Blood 96, 925-32.

3.  Blume-Jensen, P. and Hunter, T. (2001) Nature 411, 355-65.

4.  Druker, B.J. et al. (1996) Nat Med 2, 561-6.

5.  Mauro, M.J. and Druker, B.J. (2001) Curr Oncol Rep 3, 223-7.

6.  Druker, B.J. et al. (2001) N Engl J Med 344, 1031-7.

7.  Druker, B.J. et al. (2001) N Engl J Med 344, 1038-42.

8.  Ullrich, A. and Schlessinger, J. (1990) Cell 61, 203-12.

9.  Cantley, L.C. et al. (1991) Cell 64, 281-302.

10.  ten Hoeve, J. et al. (1994) Blood 84, 1731-6.

11.  Matsuguchi, T. et al. (1994) J Biol Chem 269, 5016-21.

12.  Carpino, N. et al. (1997) Cell 88, 197-204.

13.  Sattler, M. et al. (1997) Oncogene 15, 2379-84.

14.  Di Cristofano, A. et al. (1998) J Biol Chem 273, 4827-30.

15.  Wisniewski, D. et al. (1999) Blood 93, 2707-20.

16.  Kabarowski, J.H. and Witte, O.N. (2000) Stem Cells 18, 399-408.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
PathScan® is a trademark of Cell Signaling Technology, Inc.